ASAbin Sajan

Abin Sajan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abin Sajan has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Safety Outcomes and Infectious Complications Following Yttrium-90 Radioembolization in Patients with Prior Biliary Interventions: A Comprehensive Review

    by Areeb Siddiqui, Ahmed Kamel Abdel Aal, Kiyon Naser-Tavakolian, Tarub S. Mabud, Abin Sajan, Shams Iqbal, Tyler A. Sandow, Zachary T. Berman, Shamar Young, John Moody, et al.

    Background: Yttrium-90 radioembolization (Y-90) is an established locoregional therapy for primary and metastatic liver malignancies. Patients with prior biliary intervention may face a higher risk of infectious complications because of altered biliary anatomy and bacterial colonization. Objective: To evaluate the incidence of infectious complications after Y-90 radioembolization in patients with prior biliary intervention. Methods: PubMed, Embase, and Scopus were searched from inception to June 2026, and risk of bias was assessed for each study. Studies were synthesized descriptively, with per-study proportions and crude totals that count overlapping patients once. Results: Eight studies were included: six retrospective cohorts and two case reports. Four cohorts reported per-patient outcomes in 152 patients; one reported only per procedure, and another was a subset of a larger cohort. Hepatobiliary infection (liver abscess or cholangitis) occurred in 12 of 152 patients (7.9%), liver abscess in 10 (6.6%), cholangitis in 5 (3.3%), and sepsis with hepatobiliary infection in 8 (5.3%); 2 patients died of infection (1.3%). Conclusion: Hepatobiliary infection after Y-90 radioembolization in patients with prior biliary intervention appears less frequent than reported after chemoembolization but more frequent than with intact biliary anatomy. Radioembolization may be a reasonable option in this population.

  • Open Access

    Yttrium-90 Radioembolization Through Parasitized Extra-Hepatic Arteries in Hepatocellular Carcinoma: A Comprehensive Review

    by Areeb Siddiqui, Joshua D. Kuban, Shams Iqbal, Kiyon Naser-Tavakolian, Tarub S. Mabud, Abin Sajan, Ryan M. Hickey, Kirema Garcia-Reyes, Junaid Raja, Maarten L. J. Smits, et al.

    Hepatocellular carcinoma (HCC) often recruits an arterial blood supply from parasitized extra-hepatic vessels. Yttrium-90 (Y-90) radioembolization can be delivered directly through these vessels as an alternative to embolizing them to redistribute flow. This comprehensive review describes the feasibility, safety, and reported tumor response of that approach. PubMed, Embase, and Scopus were searched to June 2026, and outcomes were summarized descriptively. We included five retrospective cohorts (109 reported participants) and six case reports. All five cohorts were at serious risk of bias. The studies reported delivery through the inferior phrenic, cystic, adrenal, internal mammary, and superior mesenteric arteries. Delivery through the extra-hepatic artery was completed in every treated patient. In the four cohorts reporting tumor response, the objective response ranged from 68% to 100% and complete response from 21.1% to 76.5%, with wide confidence intervals, but nearly all patients also received hepatic-artery Y-90, so response cannot be attributed to the extra-hepatic route alone. Grade ≥ 3 toxicity occurred in 5.0% and 7.0% of patients in the two cohorts reporting it, and no radioembolization-induced liver disease was reported. No study compared direct delivery with flow redistribution, so the evidence supports feasibility and preliminary safety in selected patients rather than efficacy, and comparative studies with standardized dosimetry and reporting may be helpful.

  • Open Access

    Thermal Ablation of Hypervascular Liver Tumors After Selective Intra-Arterial Lipiodol Injection (SIALI): A Technical Narrative Review of Technique, Institutional Variations, and Published Evidence

    by Kiyon Naser-Tavakolian, Abin Sajan, Alyssa Knight, Nikhil Jacob, Stephen P. Reis, Ahmed Abdelal, Binta Patel, Michael A. Clifton, Muhammad Usman Shahid, Kirema Garcia-Reyes, et al.

    Purpose: Percutaneous thermal ablation of hypervascular liver tumors is limited by lesion conspicuity on conventional imaging, challenges with ablative margin assessment, and unequal global access to advanced technologies such as ablation confirmation software and radioembolization. This review describes the selective intra-arterial lipiodol injection (SIALI) technique, its technical variations across institutions, and summarizes published clinical outcomes for SIALI-guided thermal ablation of hepatic malignancies. Methods: A narrative review was conducted through structured searches of the PubMed, Embase, and Cochrane databases using terms including “selective intra-arterial lipiodol injection,” “lipiodol-guided ablation,” “SIALI,” and “hepatic arterial lipiodol.” Studies were selected based on relevance to SIALI technique, clinical outcomes, and comparator techniques, including hepatic arteriography with C-arm CT-guided ablation (hepACAGA) and ablation confirmation software. Full-text peer-reviewed articles were included; conference abstracts and letters were excluded. No formal PRISMA-compliant inclusion or exclusion criteria were applied, consistent with the narrative review format. Results: Seven studies were identified, encompassing six retrospective cohort studies and one prospective randomized controlled trial, collectively comprising over 900 patients treated across institutions in Asia, Europe, and the United States. Across heterogeneous patient populations and technical approaches, SIALI-guided thermal ablation was associated with improved local tumor recurrence rates, local recurrence-free survival, and overall survival compared with conventional ultrasound- or CT-guided ablation alone in selected studies where comparator data were available, with favorable technical success rates in lesions otherwise occult on standard imaging. Conclusion: SIALI appears to be a technically feasible and potentially useful adjunct technique that may improve lesion conspicuity and enable real-time ablative margin assessment in the treatment of hypervascular liver tumors, particularly in settings without access to ablation confirmation software. The available evidence is predominantly retrospective, and prospective validation is needed before broad conclusions regarding oncologic outcomes can be drawn.